Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center

Published:2019-10-22 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Liu Chang,Yu Hui,Long Qianqian,Chen Haiquan,Li Yuan,Zhao Weixin,Zhao Kuaile,Zhu Zhengfei,Sun Si,Fan Min,Chang Jianhua,Wang Jialei

Funder

Natural Science Foundation of Shanghai

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference30 articles.

1. Screening for lung cancer;Sateia;Sem Oncol,2017

2. ALK in lung cancer: past, present, and future;Shaw;J Clin Oncol,2013

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

4. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

5. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment;Zhou;BMC Cancer,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database;JTO Clinical and Research Reports;2024-08

2. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy;Medicine;2024-05-24

3. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11

4. Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review;Cureus;2023-09-19

5. Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report;OncoTargets and Therapy;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3